56248-10-3

Usage

Uses

Used in Organic Synthesis:
4-Phenyl-1H-imidazole-2-carbaldehyde is used as a reagent in organic synthesis for its ability to facilitate various chemical reactions, contributing to the creation of a wide range of compounds.
Used in Pharmaceutical and Agrochemical Product Preparation:
PIC is utilized as a building block in the development of pharmaceutical and agrochemical products, playing a crucial role in the synthesis of active ingredients.
Used in Fluorescent Detection and Analysis:
4-Phenyl-1H-imidazole-2-carbaldehyde is used as a fluorescent reagent for the detection and analysis of amino acids and proteins, providing a valuable tool in research and diagnostic applications.
Used in Drug Development:
PIC has been studied for its potential use in the development of new drugs and pharmaceutical applications, leveraging its unique chemical properties to contribute to innovative treatments and therapies.

Upstream product

• 51673-84-8 dimethoxyacetaldehyde 
• 1075-06-5 2,2-dihydroxy-1-phenyl-ethanone 
• 1260876-31-0 4-bromo-1H-imidazole-2-carbaldehyde 
• 98-80-6 phenylboronic acid 
• 162537-14-6 4-phenyl-1-(triphenylmethyl)-1H-imidazole-2-carbaldehyde 
• 1074-12-0 phenylglyoxal hydrate 

Downstream Products

• 1201687-83-3 1-(2-hydroxypropyl)-4-phenyl-1H-imidazole-2-carbaldehyde 
• 1351515-81-5 1-(4-bromobutyl)-4-phenyl-1H-imidazole-2-carbaldehyde 
• 1351515-82-6 1-phenyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carbaldehyde 

Relevant academic research and scientific papers

FERROPORTIN INHIBITORS AND METHODS OF USE

The subject matter described herein is directed to Ferroportin inhibitor compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis.

Synthesis and antimicrobial activity of new imidazole-hydrazone derivatives

Hydrazones demonstrated significant antimicrobial activity, antitubercular activity and antitumoral activity in medicinal areas. The imidazole nucleus is well known to play an important role in living organisms since it is incorporated into the histidine molecule and many other important biological, pharmacological and therapeutic activities. Condensation of 4-phenyl-1H-imidazole-2-carbaldehyde (3) with various selected benzohydrazides (4a-m) resulted in imidazole-hydrazone derivatives (5a-m). They were evaluated for antibacterial and antifungal activity against A. Niger, C. albicans (fungal strains), E. coli and P. aeruginosa (Gram-negative bacteria), S. aureus and S. pyogenes (Gram-positive bacteria) using griseofluvin (for fungi) and ciprofloxacin (for bacteria) as the standard drugs. In general, it is observed that most of the compounds were found to be potent against both the bacterial and fungal strains.

TRIAZOLO- AND PYRAZOLOQUINAZOLINE DERIVATIVES AS PDE10A ENZYME INHIBITOR

The invention relates to compounds of the formula (I) and their use as pharmaceutical ingredients, in particular for the treatment of CNS related diseases.

HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes

NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS

This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.

NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS

This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective, amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).